Concordia Healthcare Corp. (NASDAQ:CXRX) shares were up 2.6% on Wednesday . The company traded as high as $9.46 and last traded at $9.18, with a volume of 1,122,385 shares trading hands. The stock had previously closed at $8.95.

A number of research analysts have recently weighed in on CXRX shares. Zacks Investment Research raised Concordia Healthcare Corp. from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a report on Wednesday, July 13th. Goldman Sachs Group Inc. started coverage on Concordia Healthcare Corp. in a report on Monday, June 6th. They issued a “neutral” rating and a $32.00 price objective on the stock. TD Securities reissued a “buy” rating and issued a $37.00 price objective (down from $45.00) on shares of Concordia Healthcare Corp. in a report on Wednesday, June 29th. RBC Capital Markets reissued an “outperform” rating and issued a $35.00 price objective on shares of Concordia Healthcare Corp. in a report on Tuesday. Finally, CIBC lowered Concordia Healthcare Corp. from a “sector perform” rating to an “underperform” rating and set a $7.80 target price on the stock. in a report on Monday, August 15th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company. Concordia Healthcare Corp. has an average rating of “Hold” and an average price target of $39.87.

The firm’s market cap is $455.58 million. The stock has a 50-day moving average price of $15.98 and a 200 day moving average price of $24.26.

Concordia Healthcare Corp. (NASDAQ:CXRX) last released its quarterly earnings results on Friday, August 12th. The company reported $1.38 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $1.38. The business had revenue of $231.70 million for the quarter, compared to the consensus estimate of $229.76 million. The firm’s revenue was up 208.1% compared to the same quarter last year. Analysts forecast that Concordia Healthcare Corp. will post $5.35 EPS for the current fiscal year.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.